CIS-India has posted the current IPR chapter of the EU-India FTA.  The text shows the positions of Indian and EU negotiators on each provision, and it shows that India is rejecting TRIPS-Plus Enforcement provisions related to border measures for goods in transit, intermediary liability, and more severe standards for damages.  India has also noted that it cannot agree to specific copyright provisions in the trade agreement until it completes a domestic copyright reform effort that is currently under debate in Parliament.

In a statement after the release of the text, Médecins Sans Frontières (MSF) noted that the EU still advocates many TRIP-Plus measures that would jeopardize access to medicines in developing countries, and urged India to resist European pressures.  MSF purchases 80% of its pharmaceuticals from Indian generic firms.  For more, see the MSF Press Release.